Rhizopus Infection in a Preterm Infant: A Novel Use of Posaconazole.
暂无分享,去创建一个
[1] F. Kloprogge,et al. Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children , 2018, Clinical Pharmacokinetics.
[2] S. Verma. Pyomyositis in Children , 2016, Current Infectious Disease Reports.
[3] C. Lass‐Flörl,et al. Susceptibility Profiles of Amphotericin B and Posaconazole against Clinically Relevant Mucorales Species under Hypoxic Conditions , 2014, Antimicrobial Agents and Chemotherapy.
[4] R. Gorton,et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. , 2014, The Journal of antimicrobial chemotherapy.
[5] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.
[6] T. Walsh,et al. Invasive zygomycosis in neonates and children. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] H. Jafri,et al. Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age , 2008, Antimicrobial Agents and Chemotherapy.
[8] C. Subudhi. Primary Cutaneous Aspergillosis in a Preterm Neonate: Potential Therapeutic Role of Posaconazole , 2008 .
[9] R. Goldberg,et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] D. Kontoyiannis,et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.